Medical Tidbits, Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial

medical news, fda approvals, jobs in the medical field

Bagsværd, Denmark, 28 April 2016 – Novo Nordisk today announced the top-line results from the sixth and last global phase 3a trial, SUSTAIN 6, for semaglutide; a new GLP-1 analogue, which is administered subcutaneously once weekly in the SUSTAIN trials. This double-blinded trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo, both in addition to standard-of-care. In the trial, approximately 3,300 people with type 2 diabetes were treated for 104 weeks. read more

NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentations at the conference entitled “Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease” being held 4-6 May 2016 in Cambridge, United Kingdom.

The three scientific contributions submitted by the NeuroVive and Lund University research team have been accepted for poster presentation at the upcoming mitochondrial conference where global mitochondrial experts will be gathered. The posters focus on different aspects of mitochondrial disorders research and two of them are directly related to NeuroVive’s discovery platform NVP015 which has the overall goal to generate novel drug candidates that target mitochondrial energy regulation in a number of orphan diseases associated with complex I deficiency. read more

ASTRAZENECA ENTERS INTO US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD

Agreement includes US rights to Zurampic and lesinurad/allopurinol fixed-dose combination in gout

AstraZeneca today announced that it has entered into a licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic ® (lesinurad). Zurampic was approved by the US Food and Drug Administration (FDA) in December 2015 , in combination with a xanthine oxidase inhibitor (XOI), for the treatment of hyperuricemia associated with uncontrolled gout. read more

Dengue: A Global Public Health Threat That Deserves Attention

With the World Health Organization (WHO) recently declaring the Zika virus a “public health emergency of international concern,” the risk of vector-borne diseases, which are transmitted by insects like mosquitoes, has been catapulted into the global spotlight. So not surprisingly, the topic was high on the agenda when I joined a group of experts at the International Society of Neglected Tropical Diseases’ annual conference, ISNTD Bites, last month. read more

Medtronic Demonstrates Commitment to EVAR in Comparison Study of ENGAGE Global Registry and Landmark EVAR 1 Trial

Medtronic plc (NYSE:MDT) today reported on the ENGAGE global registry of experiences with the Endurant® AAA stent graft system from Medtronic with a reference to the landmark EVAR 1 Trial. ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair (EVAR) with more than 1,200 patients at 79 sites across six continents and ten-year follow-up planned for all patients. A decade ago in a breakthrough conclusion, EVAR 1 demonstrated better aneurysm-related survival for EVAR over open surgery. Today’s comparison comes from a presentation at the 2016 Charing Cross Symposium in London. read more

Teleflex Signs New Agreements with HealthTrust for LMA® Airways and Arrow® Pain Management Solutions WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced its Anesthesia Division has signed two new group purchasing agreements with HealthTrust, one for laryngeal mask airways and the other for pain management solutions. read more

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery

KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or “The Company”), announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2–6 May 2016, in Queensland, Australia read more

Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that results from the international, randomized, double-blind, placebo-controlled TOURMALINE-MM1 Phase 3 clinical study, evaluating once-weekly oral NINLARO® (ixazomib) capsules plus lenalidomide and dexamethasone versus placebo plus lenalidomide-dexamethasone in patients with relapsed and/or refractory multiple myeloma, have been published in the prestigious New England Journal of Medicine (NEJM). NINLARO was recently approved by the U.S. Food and Drug Administration (FDA), based on the pivotal TOURMALINE-MM1 data, in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  read more

Zambon Launches Xadago® (Safinamide) in Denmark and Sweden for Patients with Mid- to Late-Stage Parkinson’s Disease

MILAN–(BUSINESS WIRE)–Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced the launch of Xadago® (safinamide) in Denmark and Sweden for the treatment of mid- to late-stage Parkinson’s disease (PD). read more

 

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.